[Are there any clinical evaluations confirming higher incidence of skin cancers as a result of pimecrolimus therapy?].
Pimecrolimus (SDZ ASM 981), nonsteroid anty-inflammatory ackomycin-derived drug has more and more indications in dermatology. It has been recommended in therapy of atopic and contact dermatitis at the beginning. Nowadays pimecrolimus is used in the treatment of seborrhoic dermatitis, post-steroidal rosacea, bullous diseases etc. News reporting higher incidence of skin cancers after pimecrolimus application has not been proved clinically. The common use of mentioned medication forced us to detailed analysis of references concerning that problem.
Barańjska-Rybak
Wioletta
W
Akademia Medyczna w Gdańsku, Klinika Dermatologii, Wenerologii i Alergologii.
Nowicki
Roman
R
Sokołowska-Wojdyło
Małgorzata
M
Roszkiewicz
Jadwiga
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D015984:Causality; D015897:Comorbidity; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000453:epidemiology; D003877:Dermatitis, Contact / Q000188:drug therapy / Q000453:epidemiology; D003879:Dermatologic Agents / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus